Biomay Announces Expansion of GMP-Facilities to Offer mRNA Manufacturing and Aseptic Filling Services
Vienna, November 13, 2023
Biomay expanded its biomanufacturing facility in central Vienna, 9th district, by adding clean rooms, laboratories, and warehouse premises in the Vienna Competence Center building. Besides the 4000 sqm main site in Vienna 22nd district, Biomay now operates an additional 2000 sqm integrated biomanufacturing facility, equipped with five GMP-commissioned clean rooms for upstream and downstream processing and aseptic filling. Furthermore, the site features comprehensive laboratories for quality control, process and assay development.
A New Center of Excellence for mRNA
The upgraded site will serve as Biomay's Center of Excellence for end-to-end Contract Development and Manufacturing Organization (CDMO) services, specifically for messenger RNA (mRNA) manufacturing. The GMP service offerings for mRNA include plasmid cell banking, circular plasmid and linear DNA template manufacturing, in-vitro transcription (IVT) of mRNA drug substance, and aseptic filling of mRNA drug product. Biomay employs cutting-edge enzymatic run-off transcription based on linear DNA templates for mRNA processing, offering various options for 5´-capping, 3´-poly-adenylation, and nucleotide modification as per client requirements.
Notably, Biomay has a strong track record in GMP production of linear DNA templates, supplying significant amounts of these templates during the COVID-19 pandemic for the manufacturing of a COVID-19 mRNA vaccine. The company has also gained extensive experience in GMP manufacturing of DNA templates for other clinical indications, such as oncology.
Aseptic Filling Capacities
Biomay's aseptic filling capacities include a seven-glove isolator equipped with an automated processing line for aseptic filling, vial capping and crimping, primarily serving clinical-stage investigational medicinal products (IMPs). Dr. Angela Neubauer, the Site Head of the facility and Biomay's Senior Vice President Client Business, emphasized the company's evolution from being a drug substance and API manufacturer to offering drug product aseptic filling, testing and release services. She highlighted Biomay's strategic goal of establishing itself as a leading player in the mRNA CDMO field, alongside its existing expertise in proteins and plasmids.
Contacts
Dr. Angela NeubauerSVP Client BusinessBiomay AG
Ada Lovelace-Str. 2
A-1220 Vienna, Austria
Images
Links
About Biomay
Founded in 1984, Biomay AG is a fully integrated CDMO with a focus on microbial based GMP services for manufacturing therapeutic proteins, plasmid DNA and mRNA. The new site complements Biomay’s main manufacturing site in Vienna Seestadt (22nd district, Ada Lovelace-Strasse), established in 2021.
About news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Successor to the emporia bestseller: The smartphone that fits in every pocket25.7.2024 08:05:00 CEST | Press release
(Linz, Austria). The European smartphone company emporia is launching the successor to its previous bestseller on the market for the past 2 years. The emporiaSMART.6lite follows on from the emporiaSMART.5 - which has been voted “senior smartphone of the year” in Germany three times in a row.
37th Maschsee Festival in Hannover begins at the end of July and promises 19 days of maritime open-air flair in the heart of the city24.7.2024 13:38:07 CEST | Press release
On 31 July Maschsee Festival in Hannover will kick off for the 37th time. For 19 days – until 18 August – the capital city of Lower Saxony will host Germany’s largest lakeside festival on and around the water.
Gerhard Burits takes on new role at the ELATEC Group / RFID specialist ELATEC: New management duo with many years of experience23.7.2024 09:00:00 CEST | Press release
Munich, July 23, 2024 – Gerhard Burits expands his responsibilities and assumes the role of CEO of the ELATEC Group. Thanks to his in-depth knowledge of the company structure and his strategic foresight, he is ideally qualified to reinforce ELATEC’s position as an innovation leader in global competition. The management board will have joint leaders at the helm: Also on board is Paul Massey, who, as CEO of ELATEC Inc., is now also taking on the role of COO of the ELATEC Group and contributing his international expertise to a greater extent. Gerhard Burits, who joined the company in June 2020 as Chief Financial Officer (CFO), has been appointed Chief Executive Officer (CEO) of ELATEC GmbH. Over the past four years, he has made a significant contribution as CFO to financial stability and international growth, positioning ELATEC excellently with his strategic expertise. As CEO, he is now determined to reinforce the ELATEC Group’s technological lead, strengthen its presence on the global ma
Grünenthal acquires US-company Valinor Pharma and becomes global owner of Movantik®22.7.2024 10:05:22 CEST | Press release
Grünenthal acquires the pharmaceutical company Valinor Pharma, further strengthening Grünenthal’s footprint in the United States. With the acquisition, Grünenthal becomes the global owner of Movantik® / Moventig® (naloxegol). Since 2017, Grünenthal has invested more than €2 billion in successful M&A transactions, significantly strengthening its profitability. Aachen, Germany, 22 July 2024 – Grünenthal today announced the acquisition of US-based Valinor Pharma, LLC (“Valinor”) and its product Movantik® (naloxegol), with a total deal value of approx. $250 million inclusive of all royalty obligations. Grünenthal will finance the transaction using available liquidity. Movantik® is indicated for the oral treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. The transaction further expands Grünenthal’s portfolio of established medicines and adds to the company’s growing U.S. business. Gross sales from Movantik® in the United States reached over $200 m
FitLine becomes Official Partner of the ATP Tour18.7.2024 09:05:20 CEST | Press release
(London/Schengen, July 18th, 2024) FitLine is proud to announce a new multi-year partnership with the world’s top-tier men’s tennis tour. The athletes will benefit from the FitLine products, with the brand being the new Official Sports Nutrition Partner and Official Energy Bar Partner of the ATP Tour. The ATP Tour chose FitLine as its new Official Partner due to the shared commitment to supporting athletic performance and clean sport, both for professional and recreational athletes alike. “We’re delighted to welcome Fitline to the ATP Tour’s partner roster. The synergies between our brands are evident, with both organisations dedicated to optimising athletic performance”, said Massimo Calvelli, ATP CEO. “This partnership reflects the ATP Tour's appeal to global partners and our strength in engaging fans digitally.” FitLine’s premium products are developed and distributed exclusively by PM-International. CEO, Rolf Sorg, added, “Through our partnership with the ATP Tour, we are proud tha
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom